The Efficacy, Tolerability, and Joint Safety of Fasinumab in Osteoarthritis Pain: A Phase IIb/III Double ‐Blind, Placebo‐Controlled, Randomized Clinical Trial

ConclusionFasinumab provided improvements in OA pain and function, even in those benefitting little from previous analgesics. The observed benefit ‐to‐risk relationship favors further clinical development to explore the lowest doses of fasinumab in patients with knee or hip OA.

Source: Arthritis and Rheumatology - September 19, 2019 Category: Rheumatology Authors: Paula Dakin, Stephen J. DiMartino, Haitao Gao, Jennifer Maloney, Alan J. Kivitz, Thomas J. Schnitzer, Neil Stahl, George D. Yancopoulos, Gregory P. Geba Tags: Original Article Source Type: research